Cannabidiol (CBD) use in psychiatric disorders: A systematic review.
Bonaccorso S, Ricciardi A, Zangani C, Chiappini S, Schifano F.
Neurotoxicology. 2019 Sep;74:282-298. doi: 10.1016/j.neuro.2019.08.002. Epub 2019 Aug 11. Review.
PMID:31412258
S-adenosyl-l-methionine (SAMe), cannabidiol (CBD), and kratom in psychiatric disorders: Clinical and mechanistic considerations.
Taylor Levine M, Gao J, Satyanarayanan SK, Berman S, Rogers JT, Mischoulon D.
Brain Behav Immun. 2019 Jul 10. pii: S0889-1591(19)30278-8. doi: 10.1016/j.bbi.2019.07.013. [Epub ahead of print] Review.
PMID:31301401
Cannabidiol as a Novel Candidate Alcohol Use Disorder Pharmacotherapy: A Systematic Review.
Turna J, Syan SK, Frey BN, Rush B, Costello MJ, Weiss M, MacKillop J.
Alcohol Clin Exp Res. 2019 Apr;43(4):550-563. doi: 10.1111/acer.13964. Epub 2019 Feb 19. Review.
PMID:30698831
Cannabis and Mood Disorders.
Lucatch AM, Coles AS, Hill KP, George TP.
Curr Addict Rep. 2018 Sep;5(3):336-345. doi: 10.1007/s40429-018-0214-y. Epub 2018 May 10.
PMID:30643708
Free PMC Article
Antidepressant-like effect induced by Cannabidiol is dependent on brain serotonin levels.
Sales AJ, Crestani CC, Guimarães FS, Joca SRL.
Prog Neuropsychopharmacol Biol Psychiatry. 2018 Aug 30;86:255-261. doi: 10.1016/j.pnpbp.2018.06.002. Epub 2018 Jun 6.
PMID:29885468
Review of the neurological benefits of phytocannabinoids.
Maroon J, Bost J.
Surg Neurol Int. 2018 Apr 26;9:91. doi: 10.4103/sni.sni_45_18. eCollection 2018. Review.
PMID:29770251
Free PMC Article
The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial.
Boggs DL, Surti T, Gupta A, Gupta S, Niciu M, Pittman B, Schnakenberg Martin AM, Thurnauer H, Davies A, D'Souza DC, Ranganathan M.
Psychopharmacology (Berl). 2018 Jul;235(7):1923-1932. doi: 10.1007/s00213-018-4885-9. Epub 2018 Apr 5.
PMID:29619533
Drug-drug interactions as a result of co-administering Δ9-THC and CBD with other psychotropic agents.
Rong C, Carmona NE, Lee YL, Ragguett RM, Pan Z, Rosenblat JD, Subramaniapillai M, Shekotikhina M, Almatham F, Alageel A, Mansur R, Ho RC, McIntyre RS.
Expert Opin Drug Saf. 2018 Jan;17(1):51-54. doi: 10.1080/14740338.2017.1397128. Epub 2017 Oct 31. Review.
PMID:29082802
Cannabidiol in medical marijuana: Research vistas and potential opportunities.
Rong C, Lee Y, Carmona NE, Cha DS, Ragguett RM, Rosenblat JD, Mansur RB, Ho RC, McIntyre RS.
Pharmacol Res. 2017 Jul;121:213-218. doi: 10.1016/j.phrs.2017.05.005. Epub 2017 May 10. Review.
PMID:28501518
Fluorinated Cannabidiol Derivatives: Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects.
Breuer A, Haj CG, Fogaça MV, Gomes FV, Silva NR, Pedrazzi JF, Del Bel EA, Hallak JC, Crippa JA, Zuardi AW, Mechoulam R, Guimarães FS.
PLoS One. 2016 Jul 14;11(7):e0158779. doi: 10.1371/journal.pone.0158779. eCollection 2016. Erratum in: PLoS One. 2016;11(8):e0162087.
PMID:27416026
Free PMC Article
Prohedonic Effect of Cannabidiol in a Rat Model of Depression.
Shoval G, Shbiro L, Hershkovitz L, Hazut N, Zalsman G, Mechoulam R, Weller A.
Neuropsychobiology. 2016;73(2):123-9. doi: 10.1159/000443890. Epub 2016 Mar 25.
PMID:27010632
Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT1A receptors.
Linge R, Jiménez-Sánchez L, Campa L, Pilar-Cuéllar F, Vidal R, Pazos A, Adell A, Díaz Á.
Neuropharmacology. 2016 Apr;103:16-26. doi: 10.1016/j.neuropharm.2015.12.017. Epub 2015 Dec 19.
PMID:26711860
Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa.
de Mello Schier AR, de Oliveira Ribeiro NP, Coutinho DS, Machado S, Arias-Carrión O, Crippa JA, Zuardi AW, Nardi AE, Silva AC.
CNS Neurol Disord Drug Targets. 2014;13(6):953-60. Review.
PMID:24923339
Acute and chronic administration of cannabidiol increases mitochondrial complex and creatine kinase activity in the rat brain.
Valvassori SS, Bavaresco DV, Scaini G, Varela RB, Streck EL, Chagas MH, Hallak JE, Zuardi AW, Crippa JA, Quevedo J.
Braz J Psychiatry. 2013 Oct-Dec;35(4):380-6. doi: 10.1590/1516-4446-2012-0886. Epub 2013 Dec 23.
PMID:24402213
Free Article
Endocannabinoid system and mood disorders: priming a target for new therapies.
Micale V, Di Marzo V, Sulcova A, Wotjak CT, Drago F.
Pharmacol Ther. 2013 Apr;138(1):18-37. doi: 10.1016/j.pharmthera.2012.12.002. Epub 2012 Dec 20. Review.
PMID:23261685
Endocannabinoid system dysfunction in mood and related disorders.
Ashton CH, Moore PB.
Acta Psychiatr Scand. 2011 Oct;124(4):250-61. doi: 10.1111/j.1600-0447.2011.01687.x. Epub 2011 Mar 9. Review.
PMID:21916860
The Potential Role of Cannabinoids in Modulating Serotonergic Signaling by Their Influence on Tryptophan Metabolism.
Jenny M, Schröcksnadel S, Überall F, Fuchs D.
Pharmaceuticals (Basel). 2010 Aug 13;3(8):2647-2660. Review.
PMID:27713369